Search results for "Revascularisation"

showing 5 items of 5 documents

Intérêt du growth differentiation factor 15 (GDF15) comme biomarqueur pronostique après la survenue d'un Accident Vasculaire Cérébral ischémique (AVC)

2018

Introduction Le GDF15 est un biomarqueur de mauvais pronostic dans certaines pathologies cardiovasculaires comme le syndrome coronarien aigu. Son interet dans le domaine de AVC n’a ete que peu etudie a ce jour. Objectifs Notre travail consistait a l’evaluation des taux de GDF15 chez des patients hospitalises a la phase aigue d’un AVC ischemique traites par fibrinolyse et/ou thrombectomie. L’objectif principal etait d’evaluer l’association entre les taux de GDF15 et la recuperation fonctionnelle a 3 mois. Methodes Au total, 174 patients ont ete inclus entre le 16/01 et le 30/09/2017. Le consentement etait recueilli oralement. Des prelevements biologiques ont ete realises a l’admission du pat…

AVC03 medical and health sciencesRevascularisation0302 clinical medicineBiomarqueurNeurology[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]030212 general & internal medicineNeurology (clinical)ischémique[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology030217 neurology & neurosurgery
researchProduct

Editor's Choice – Follow-up of Patients After Revascularisation for Peripheral Arterial Diseases: A Consensus Document From the European Society of C…

2019

International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often chall…

Disease030204 cardiovascular system & hematology030230 surgeryPostoperative Complications0302 clinical medicineRestenosisRecurrenceSecondary Preventionfollow-upRandomized Controlled Trials as TopicUltrasonography Doppler Duplexmedicine.diagnostic_test3. Good healthEuropeSystematic reviewPractice Guidelines as TopicIN-STENT RESTENOSISCardiologyCardiology and Cardiovascular MedicineVascular Surgical ProceduresReoperationmedicine.medical_specialtyConsensusRevascularisationINFRAINGUINAL VEIN BYPASSMEDLINEPhysical examinationSTENOSIS03 medical and health sciencesrestenosisperipheral arterial diseaseInternal medicinemedicineHumansANGIOPLASTYVELOCITY CRITERIAbusiness.industryMagnetic resonance imagingNATURAL-HISTORYPerioperativeVascular surgery3126 Surgery anesthesiology intensive care radiologymedicine.diseaseDUPLEX ULTRASOUND SURVEILLANCEENDOVASCULAR TREATMENTRISK-FACTORSSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCAROTID-ARTERYbusiness
researchProduct

Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working …

2019

International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often chall…

Epidemiologymedicine.medical_treatmentDiseaseFibromuscular dysplasia030204 cardiovascular system & hematology0302 clinical medicinefollow-up030212 general & internal medicineSocieties Medicalmedicine.diagnostic_test3. Good healthEuropeNatural historyTreatment OutcomeIN-STENT RESTENOSISCardiology030211 gastroenterology & hepatologyCardiology and Cardiovascular MedicineVascular Surgical Proceduresmedicine.medical_specialtyConsensusRevascularisationFIBROMUSCULAR DYSPLASIAINFRAINGUINAL VEIN BYPASSPhysical examinationRevascularizationSTENOSISrestenosis03 medical and health sciencesperipheral arterial diseaseInternal medicinemedicineHumansVELOCITY CRITERIAbusiness.industryNATURAL-HISTORYPerioperativeVascular surgery3126 Surgery anesthesiology intensive care radiologymedicine.diseaseStenosisDUPLEX ULTRASOUND SURVEILLANCEENDOVASCULAR TREATMENT3121 General medicine internal medicine and other clinical medicineRISK-FACTORSSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCAROTID-ARTERYbusiness030217 neurology & neurosurgeryFollow-Up StudiesEuropean Journal of Preventive Cardiology
researchProduct

Early and midterm outcomes of bioresorbable vascular scaffolds for ostial coronary lesions: insights from the GHOST-EU registry.

2016

Aims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset, with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term, but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA), left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death, target vessel m…

LCX (29Target lesionMale52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostialp= 0.035)medicine.medical_treatmentMyocardial Infarction304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14Coronary Artery Disease030204 cardiovascular system & hematologyCoronary artery diseasebut their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA)0302 clinical medicineAbsorbable Implants030212 general & internal medicineMyocardial infarctionCircumflexRegistriesTissue Scaffolds32%)Drug-Eluting StentsMiddle AgedThrombosisCoronary VesselsAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subset with higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long term but their safety in this setting remains to be explored. Methods and results: Procedural and 12-month follow-up data from consecutive patients treated with BVS for lesions located at the ostium of the right (RCA) left anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular death target vessel myocardial infarction or target lesion revascularisation. The database included a total of 1549 lesions in 1304 patients with a mean age of 62 +/- 11years. There were 90 ostial lesions (5.8%) in 84 patients (6.4%) located at the ostial RCA (14; 16%) LCX (29; 32%) or LAD (47; 52%). Patients presenting with ostial lesions did not differ from the remaining cohort except for a higher incidence of prior revascularisation. Predilation was performed in 97% of the lesions (vs. 96% in non-ostial p= 0.618) post-dilation in 43% (versus 58% in the non-ostial group p= 0.008). At quantitative coronary angiography treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37] p= 0.035) but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groups respectively log-rank p= 0.005). The device-oriented composite endpoint occurred respectively in 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025 HR 2.65 [1.41-4.97]).OstiumAims: We aimed to investigate the outcomes of bioresorbable vascular scaffolds (BVS) in coronary ostial lesions. Ostial lesions represent a challenging angiographic subsetTreatment Outcomein 12.6% and 4.6% at 12 months (log-rank p= 0.001). Treatment of ostial lesions was an independent predictor of this endpoint (p= 0.0025CardiologyFemale549 lesions in 1medicine.symptomCardiology and Cardiovascular MedicineAdultpost-dilation in 43% (versus 58% in the non-ostial groupmedicine.medical_specialtyor LAD (47HR 2.65 [1.41-4.97])but no difference in minimum lumen diameter existed (p= 0.447). Follow-up data were available at 385 [362-465] days. The 12-month Kaplan-Meier estimated rates of scaffold thrombosis were 4.9% and 2.0% (ostial and non-ostial lesion groupsrespectivelyLesion03 medical and health sciencesPercutaneous Coronary Interventionwith higher event rates compared with non-ostial lesions. BVS might be associated with advantages over the long termleft anterior (LAD) or circumflex (LCX) coronary in 11 European centres were collected. The primary device-oriented endpoint was defined as a combination of cardiovascular deathInternal medicinemedicineHumanstarget vessel myocardial infarction or target lesion revascularisation. The database included a total of 1Agedp= 0.008). At quantitative coronary angiographybusiness.industryPercutaneous coronary interventionp= 0.618)treatment of ostial lesions was associated with higher residual stenosis (30% [23-41] vs. 26% [20-37]log-rank p= 0.005). The device-oriented composite endpoint occurredmedicine.diseaseSurgery16%)businessEuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology
researchProduct

Temporary occlusions of coronaries arteries by thermoreversible gel : leGoo.To experimental to human case

2011

ObjectifsThe objective of this work is to assess the feasibility of using the LeGoo gel to occlude the coronary arteries temporarily, to facilitate the performance of coronary bypass (off-pump technique), initially in pigs then in human. A Secondary objective was to evaluate the impact of the injection on the endothelium and myocardium.MethodesThe first study evaluated in pigs the feasibility of using LeGoo, while performing coronary bypass on the left anterior descending or on the right coronary artery and to evaluate the endothelial function of coronary arteries occluded by the gel.The second study analyzed endothelial function of internal thoracic arteries, in the area occluded by the ge…

[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyCœur battant[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyRevascularisation coronaireArtère coronaireEndothéliumGel thermosensibleThermosensitive gelCoronary arteryCoronary revascularizationBeating heartOff pump[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct